WSJ

09 Jun 2026, 06:29 UTC · 2h ago

GSK to Buy Nuvalent for $10.6 Billion in Oncology Push

ShareX LinkedIn

Read original · https://www.wsj.com/business/deals/gsk-to-buy-nuvalent-for-10-6-billion-in-oncology-push-8ae5c408

Search tags

Story key points

1 claims · impact-rated

What matters in this story

1
GSK is acquiring three lung cancer drug candidates, two of which are awaiting FDA approval decisions this year. — The imminent potential for two new FDA-approved revenue streams in a high-value therapeutic area is a strong positive catalyst for GSK.
+0.60

Ticker attribution

Model heads

Sentiment in this article

GSK+0.80
The company is acquiring three lung cancer drug candidates, two of which are pending FDA approval.

Relationships in this article

No ticker relationship head found.

Early access

You’re reading about it. Someone else is already positioned.

News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.

Browse live screenings

Impact vectors

2 dimensions · 9 clusters

6 related stories

Proactive Investors
2h ago
GSK agrees $10.6bn Nuvalent takeover to bolster oncology pipeline
- biotech
- fda
- lung cancer
Read

GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | News Impact… · News Impact Screener

GSK to Buy Nuvalent for $10.6 Billion in Oncology Push

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

GSK agrees $10.6bn Nuvalent takeover to bolster oncology pipeline

GSK to Buy Nuvalent for $10.6 Billion in Oncology Push

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

GSK agrees $10.6bn Nuvalent takeover to bolster oncology pipeline

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down

UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

GSK in talks to buy cancer biotech Nuvalent for more than $9 billion, FT reports

GSK to Buy Nuvalent for $10.6 Billion in Oncology Push

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Next reads from the same story arc

GSK agrees $10.6bn Nuvalent takeover to bolster oncology pipeline

GSK to Buy Nuvalent for $10.6 Billion in Oncology Push

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Next reads from the same story arc

GSK agrees $10.6bn Nuvalent takeover to bolster oncology pipeline

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down

UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

GSK in talks to buy cancer biotech Nuvalent for more than $9 billion, FT reports